Compare KLA Corp. (KLAC) vs State Street SPDR S&P Biotech ETF (XBI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
KLA Corp. vs State Street SPDR S&P Biotech ETF — how do they compare? KLA Corp. trades at $195.57 (market cap $256.72B), while State Street SPDR S&P Biotech ETF trades at $153.75 (market cap $10.11B). The key difference: KLA Corp. is far larger — about 25.4× State Street SPDR S&P Biotech ETF's market cap, and KLA Corp. pays a 0.47% dividend while State Street SPDR S&P Biotech ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold KLA Corp. for 60 Days and State Street SPDR S&P Biotech ETF for 38 Days on average.
| KLAC | XBI | |
|---|---|---|
Market Cap | $256.72B | $10.11B |
Volume | 9,970,753 | 12,903,266 |
Sector | Technology | Broad Market / Factor |
52-Week High | $301.71 | $169.55 |
52-Week Low | $98.28 | $104.99 |
Typical Hold Time | 60 Days | 38 Days |
Enterprise Value | $257.97B | — |
Dividend Yield | 0.47% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
KLA Corporation (KLAC) trades at $196.72, showing slight daily weakness but maintaining a strong uptrend supported by bullish technical indicators and robust fundamentals. The company reported revenue of $12.16 billion in 2025 with a net income margin of 35.57%, and has consistently beaten earnings expectations in recent quarters. AI-driven demand is fueling growth, with a backlog of $12.57 billion highlighting strong future revenue visibility.
The outlook for KLAC remains positive, driven by semiconductor equipment demand from AI and advanced packaging. Key opportunities include market leadership in inspection and metrology, while risks involve competitive pressures from Applied Materials and ASML, and execution challenges in scaling operations. The consensus price target of $223.88 suggests significant upside potential from current levels.
XBI trades at $149.29, down 0.63% on the day, with technical indicators showing a bearish bias despite oversold RSI conditions. The ETF faces mixed sentiment with 100% hold ratings from analysts but positive catalysts from biotech breakthroughs. Recent news highlights XBI's 76% rally over the past year and ongoing M&A activity driving sector optimism.
Outlook remains cautiously optimistic with potential upside from cancer vaccine developments and sector consolidation, though high volatility and expense ratios relative to broader healthcare ETFs present risks. The ETF's modified equal-weight structure offers diversified exposure to 150+ biotech names, benefiting from improved capital access and clinical trial catalysts.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About KLA Corp.
KLA designs and manufactures yield-management and process-monitoring diagnostic and control systems for the semiconductor manufacturing industry. The systems are used to analyze the manufacturing process at various steps in a semiconductor's development. The firm's laser-scanning products are used for wafer qualification, process monitoring, and equipment monitoring. KLA also provides inspection tools and systems for optical metrology and e-beam metrology.
Read more on KLAC →About State Street SPDR S&P Biotech ETF
XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →
